Organon & Co. (OGN)
Organon & Co. Statistics
Share Statistics
Organon & Co. has 257.95M shares outstanding. The number of shares has increased by 0.74% in one year.
Shares Outstanding | 257.95M |
Shares Change (YoY) | 0.74% |
Shares Change (QoQ) | 0.03% |
Owned by Institutions (%) | 80.07% |
Shares Floating | 257.25M |
Failed to Deliver (FTD) Shares | 598 |
FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 18.23M, so 7.08% of the outstanding shares have been sold short.
Short Interest | 18.23M |
Short % of Shares Out | 7.08% |
Short % of Float | 7.09% |
Short Ratio (days to cover) | 4.12 |
Valuation Ratios
The PE ratio is 4.44 and the forward PE ratio is 3.92. Organon & Co.'s PEG ratio is -0.27.
PE Ratio | 4.44 |
Forward PE | 3.92 |
PS Ratio | 0.6 |
Forward PS | 0.6 |
PB Ratio | 8.13 |
P/FCF Ratio | 5.02 |
PEG Ratio | -0.27 |
Enterprise Valuation
Organon & Co. has an Enterprise Value (EV) of 11.75B.
EV / Earnings | 13.6 |
EV / Sales | 1.83 |
EV / EBITDA | 7.32 |
EV / EBIT | 7.91 |
EV / FCF | 15.38 |
Financial Position
The company has a current ratio of 1.6, with a Debt / Equity ratio of 18.81.
Current Ratio | 1.6 |
Quick Ratio | 1.11 |
Debt / Equity | 18.81 |
Total Debt / Capitalization | 94.95 |
Cash Flow / Debt | 0.11 |
Interest Coverage | 2.86 |
Financial Efficiency
Return on equity (ROE) is 1.83% and return on capital (ROIC) is 17.01%.
Return on Equity (ROE) | 1.83% |
Return on Assets (ROA) | 0.07% |
Return on Capital (ROIC) | 17.01% |
Revenue Per Employee | $640,300 |
Profits Per Employee | $86,400 |
Employee Count | 10,000 |
Asset Turnover | 0.49 |
Inventory Turnover | 2.03 |
Taxes
Income Tax | -57M |
Effective Tax Rate | -0.07 |
Stock Price Statistics
The stock price has increased by -22.5% in the last 52 weeks. The beta is 0.72, so Organon & Co.'s price volatility has been higher than the market average.
Beta | 0.72 |
52-Week Price Change | -22.5% |
50-Day Moving Average | 15.37 |
200-Day Moving Average | 17.76 |
Relative Strength Index (RSI) | 41.13 |
Average Volume (20 Days) | 3.33M |
Income Statement
In the last 12 months, Organon & Co. had revenue of 6.4B and earned 864M in profits. Earnings per share was 3.36.
Revenue | 6.4B |
Gross Profit | 3.71B |
Operating Income | 1.49B |
Net Income | 864M |
EBITDA | 1.6B |
EBIT | 1.49B |
Earnings Per Share (EPS) | 3.36 |
Balance Sheet
The company has 675M in cash and 8.88B in debt, giving a net cash position of -8.21B.
Cash & Cash Equivalents | 675M |
Total Debt | 8.88B |
Net Cash | -8.21B |
Retained Earnings | 1.01B |
Total Assets | 13.1B |
Working Capital | 1.63B |
Cash Flow
In the last 12 months, operating cash flow was 939M and capital expenditures -175M, giving a free cash flow of 764M.
Operating Cash Flow | 939M |
Capital Expenditures | -175M |
Free Cash Flow | 764M |
FCF Per Share | 2.97 |
Margins
Gross margin is 58.02%, with operating and profit margins of 23.21% and 13.49%.
Gross Margin | 58.02% |
Operating Margin | 23.21% |
Pretax Margin | 12.6% |
Profit Margin | 13.49% |
EBITDA Margin | 25.05% |
EBIT Margin | 23.21% |
FCF Margin | 11.93% |
Dividends & Yields
OGN pays an annual dividend of $1.4, which amounts to a dividend yield of 7.43%.
Dividend Per Share | $1.40 |
Dividend Yield | 7.43% |
Dividend Growth (YoY) | 0% |
Payout Ratio | 42.04% |
Earnings Yield | 23.06% |
FCF Yield | 20.33% |
Analyst Forecast
The average price target for OGN is $20, which is 37.3% higher than the current price. The consensus rating is "Hold".
Price Target | $20 |
Price Target Difference | 37.3% |
Analyst Consensus | Hold |
Analyst Count | 5 |
Scores
Altman Z-Score | 1.28 |
Piotroski F-Score | 5 |